StockData
Opus Genetics, Inc. logo

Opus Genetics, Inc. (IRD) stock

IRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30483% above fair value
$4.06−0.25 (-5.80%)

Close on Nov 12, 2026Market cap $337.78MP/E –Yield –

Opus Genetics operating margin

Operating margin is operating income as a percentage of revenue.

Opus Genetics's operating margin for the twelve months ending Sep 30, 2026 was -777.7%. For fiscal 2025 it was -271.9%, against -564.7% the year before. The highest annual figure on record is 45.7% in fiscal 2022.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-271.9%+292.8
FY2024Dec 31, 2024-564.7%−509.3
FY2023Dec 31, 2023-55.5%−101.2
FY2022Dec 31, 202245.7%+3900.6
FY2021Dec 31, 2021-3854.8%−3715.1
FY2019Dec 31, 2019-139.8%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 2026-1692.8%−1422.9
Q2 FY2026Jun 30, 2026-2182.8%−1873.8
Q1 FY2026Mar 31, 2026-665.9%−438.7
Q4 FY2025Dec 31, 2025-296.3%+587.7
Q3 FY2025Sep 30, 2025-269.9%−62.8
Q2 FY2025Jun 30, 2025-309.0%+439.9
Q1 FY2025Mar 31, 2025-227.2%+223.3
Q4 FY2024Dec 31, 2024-884.0%−562.9
Q3 FY2024Sep 30, 2024-207.1%−260.6
Q2 FY2024Jun 30, 2024-748.9%−602.2
Q1 FY2024Mar 31, 2024-450.5%−100.0
Q4 FY2023Dec 31, 2023-321.1%−406.9
Q3 FY2023Sep 30, 202353.5%+918.9
Q2 FY2023Jun 30, 2023-146.7%+6990.3
Q1 FY2023Mar 31, 2023-350.5%−112.7
Q4 FY2022Dec 31, 202285.8%+217.1
Q3 FY2021Sep 30, 2021-865.4%–
Q2 FY2021Jun 30, 2021-7137.0%–
Q1 FY2020Mar 31, 2020-237.8%–
Q1 FY2019Mar 31, 2019-131.3%–

More Opus Genetics figures

See a number that looks wrong?